New oral anticoagulants and laboratory monitoring;Nouveaux anticoagulants par voie orale: Quelle place pour les analyses de biologie médicale?

Sang Thrombose Vaisseaux

Volumn 23, Issue 1, 2011, Pages 8-17

  Gouin Thibault, Isabelle ^a,b   Mismetti, Patrick ^c   Flaujac, Claire ^b   Delavenne, Xavier ^c   Laporte, Silvy ^c   Loriot, Marie Anne ^d   Lecompte, Thomas ^e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔTEL DIEU   (France)

^c University Jean Monnet of Saint Etienne EA3065   (France)

^d INSERM   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Dabigatran; Laboratory tests; Orally available anticoagulants; Rivaroxaban

Indexed keywords

DABIGATRAN ETEXILATE; LUPUS ANTICOAGULANT; RIVAROXABAN;

ARTICLE; BIOAVAILABILITY; BLOOD CLOTTING TEST; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; GERIATRIC PATIENT; HUMAN; KIDNEY DISEASE; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PHYSICIAN; POLYPHARMACY; PROTHROMBIN TIME; RISK ASSESSMENT; THROMBIN TIME; THROMBOEMBOLISM;

EID: 79958802001     PISSN: 09997385     EISSN: 19506104     Source Type: Journal    
DOI: 10.1684/stv.2011.0563     Document Type: Article

References (22)

1. EMEA. Rapport européen public d'évaluation-Pradaxa. http://www.emea.europa.eu; 2008.
2. EMEA. Rapport européen public d'évaluation-Xarelto. http://www.emea.europa.eu; 2008.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versuswarfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
4. Mahaffey K. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarine in patients with non-valvular atrial fibrillation (ROCKET-AF). Congrès de l'American Heart Association 2010.
5. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
6. Buller H. Einstein-DVT. European Society of Cardiology 2010.
7. Eriksson BI, Kakkar AK, Turpie AGG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg 2009; 91-B: 636-44.
8. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15.
9. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
10. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet 2010; 49: 259-68.
11. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-21.
12. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-80.
13. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-63.
14. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-16.
15. Prise en charge des surdosages en AVK, des situations à risques hémorragiques chez les patients traités par antivitamine K en ville et en milieu hospitalier. www.has-sante.fr; 2008.
16. SamamaMM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-25.
17. Samama MM, Amiral J, Guinet C, et al. An optimised, rapid chromogenic assay, specific for measuring direct factorXainhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104: 1078-9.
18. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
19. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-95.
20. Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with Calibrated Automated Thrombography. Thromb Res 2011; 127: 29-34.
21. Mismetti P, Laporte S. Neworal antithrombotics: a need for laboratory monitoring For. J Thromb Haemost. 2010; 8: 621-6.
22. Camm J. The new ESC guidelines: Atrial fibrillation. Congress of the European Society of Cardiology 2010.